TY - JOUR
T1 - PONDx
T2 - real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
AU - Cognetti, Francesco
AU - Masetti, Riccardo
AU - Fabi, Alessandra
AU - Bianchi, Giulia
AU - Santini, Donatella
AU - Rognone, Alessia
AU - Catania, Giovanna
AU - Angelucci, Domenico
AU - Naso, Giuseppe
AU - Giuliano, Mario
AU - Vassalli, Lucia
AU - Vici, Patrizia
AU - Scognamiglio, Giovanni
AU - Generali, Daniele
AU - Zambelli, Alberto
AU - Colleoni, Marco
AU - Tinterri, Corrado
AU - Scanzi, Francesco
AU - Vigna, Leonardo
AU - Scavina, Paola
AU - Gamucci, Teresa
AU - Marrazzo, Emilia
AU - Scinto, Angelo Fedele
AU - Berardi, Rossana
AU - Fabbri, Maria Agnese
AU - Pinotti, Graziella
AU - Franco, Daniela
AU - Terribile, Daniela Andreina
AU - Tonini, Giuseppe
AU - Cianniello, Daniela
AU - Barni, Sandro
N1 - Funding Information:
We thank the participating physicians and treatment centers for their contribution to this study. We also thank all patients for their willingness to participate. This work was supported by Genomic Health, Inc., by providing the Oncotype DX Breast Recurrence Score® test for the participating patients and by funding the Editorial assistance provided by Markus Fischer (Fischer BioMedical Wissenschaftskommunikation, Homburg/Saar, Germany).
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype DX Breast Recurrence Score® (RS) assay has been demonstrated to predict CT benefit, hence supporting personalized decisions on adjuvant CT. The multicenter, prospective, observational study PONDx investigated the real-life use of RS® results in Italy and its impact on treatment decisions. Physicians’ treatment recommendations (HT ± CT) were documented before and after availability of RS results, and changes in recommendations were determined. In the HR+ HER2− early BC population studied (N = 1738), physicians recommended CT + HT in 49% of patients pre-RS. RS-guided treatment decisions resulted in 36% reduction of CT recommendations. PONDx confirms that RS results provide clinically relevant information for CT recommendation in early-stage BC, resulting in a reduction of more than a third of CT use.
AB - Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype DX Breast Recurrence Score® (RS) assay has been demonstrated to predict CT benefit, hence supporting personalized decisions on adjuvant CT. The multicenter, prospective, observational study PONDx investigated the real-life use of RS® results in Italy and its impact on treatment decisions. Physicians’ treatment recommendations (HT ± CT) were documented before and after availability of RS results, and changes in recommendations were determined. In the HR+ HER2− early BC population studied (N = 1738), physicians recommended CT + HT in 49% of patients pre-RS. RS-guided treatment decisions resulted in 36% reduction of CT recommendations. PONDx confirms that RS results provide clinically relevant information for CT recommendation in early-stage BC, resulting in a reduction of more than a third of CT use.
UR - http://www.scopus.com/inward/record.url?scp=85105350378&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105350378&partnerID=8YFLogxK
U2 - 10.1038/s41523-021-00246-4
DO - 10.1038/s41523-021-00246-4
M3 - Article
AN - SCOPUS:85105350378
VL - 7
JO - npj Breast Cancer
JF - npj Breast Cancer
SN - 2374-4677
IS - 1
M1 - 47
ER -